Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Radiology

26-03-2024 | Oligodendroglioma | Commentary

Perfusion percentage signal recovery and a mundane chicken wire: what could they have to do in oligodendrogliomas?

Author: Elaine Lui

Published in: European Radiology

Login to get access

Excerpt

Diffuse gliomas are the most common adult primary brain tumours [1]. This tumour family has undergone further revision in the latest 2021 WHO classification of CNS tumours, now simplified and consolidated to three tumour types under “adult-type diffuse gliomas”: astrocytoma IDH-mutant (1p/19q noncodeleted), oligodendroglioma (IDH-mutant, 1p/19q-codeleted) and glioblastoma IDH-wildtype [2]. Depending primarily on their respective molecular signatures, each type has distinct prognosis to treatment [1, 3]. IDH-mutant tumours with 1p/19q-codeletion have been shown to respond more robustly to adjuvant procarbazine, lomustine and vincristine chemotherapy than those without 1p/19q-codeletion [4]. Novel treatment options with IDH inhibitors, currently undergoing clinical trials, are also on the horizon for IDH-mutant tumours [1]. …
Literature
1.
van den Bent MJ, Geurts M, French PJ et al (2023) Primary brain tumours in adults. Lancet 402:1564–1579CrossRefPubMed
2.
3.
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498CrossRef
4.
Lassman AB, Hoang-Xuan K, Polley M-YC et al (2022) Joint Final Report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors. J Clin Oncol 40:2539–2545CrossRefPubMedPubMedCentral
5.
Lasocki A, Buckland ME, Drummond KJ et al (2022) Conventional MRI features can predict the molecular subtype of adult grade 2–3 intracranial diffuse gliomas. Neuroradiology 64:2295–2305CrossRefPubMedPubMedCentral
6.
Do YA, Cho SJ, Choi BS et al (2022) Predictive accuracy of T2-FLAIR mismatch sign for the IDH-mutant, 1p/19q noncodeleted low-grade glioma: an updated systematic review and meta-analysis. Neuro Oncol Adv 4:vdac010CrossRef
7.
8.
9.
Pons-Escoda A, Garcia-Ruiz A, Naval-Baudin P et al (2024) Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles. Eur Radiol. https://​doi.​org/​10.​1007/​s00330-024-10611-z
10.
Boxerman JL, Paulson ES, Prah MA, Schmainda KM (2013) The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: implications for clinical applications. AJNR Am J Neuroradiol 34:1364–1369CrossRefPubMedPubMedCentral
11.
Ahamed MF, Hossain MM, Nahiduzzaman et al (2023) A review on brain tumor segmentation based on deep learning methods with federated learning techniques. Comput Med Imaging Graph 110:102313CrossRefPubMed
Metadata
Title
Perfusion percentage signal recovery and a mundane chicken wire: what could they have to do in oligodendrogliomas?
Author
Elaine Lui
Publication date
26-03-2024
Publisher
Springer Berlin Heidelberg
Published in
European Radiology
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-024-10711-w